BRIEF-GSK gets accelerated FDA approval for combination use of Mekinist and Tafinlar

Wed Jan 8, 2014 8:47pm EST

Related Topics

Jan 9 (Reuters) - GlaxoSmithKline Plc : * Says gains accelerated FDA approval for combination use of

Mekinist(trametinib) and Tafinlar (dabrafenib) * Mekinist, Tafinlar approved for patients with unresectable melanoma or

metastatic melanoma with BRAF V600E or V600K mutations *

FILED UNDER: